Why has NICE said this?
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.
Erlotinib was recommended because the benefits to patients with non‑small‑cell lung cancer, with EGFR status that is either positive or unknown, justify its cost.
Gefitinib was not recommended because it was not clear from the evidence whether the benefits to patients justify its cost.